Tetrathiomolybdate is effective in a mouse model of arthritis

Journal of Rheumatology

Volumn 33, Issue 12, 2006, Pages 2501-2506

  McCubbin, Mark D ^a   Hou, Guoqing ^a   Abrams, Gerald D ^a   Dick, Robert ^a   Zhang, Zhan ^a   Brewer, George J ^b  

^a Department of Human Genetics ^*

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Arthritis; Copper; Interleukin 1 ; Interleukin 2; Isoprostane; Tetrathiomolybdate; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; CERULOPLASMIN; COLLAGEN TYPE 2; COPPER; CYTOKINE; FORMALDEHYDE; INTERLEUKIN 1BETA; INTERLEUKIN 2; ISOPROSTANE; OXIDIZING AGENT; TETRATHIOMOLYBDIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; HINDLIMB; JOINT SWELLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; URINALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CERULOPLASMIN; CHELATING AGENTS; COPPER; CYTOKINES; EDEMA; ERYTHEMA; ISOPROSTANES; JOINTS; MALE; MICE; MICE, INBRED DBA; MOLYBDENUM; TREATMENT OUTCOME; WATER SUPPLY;

EID: 33846110887     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:379-85.
2. Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 1981;14:189-207.
3. Bremner I, Mills CF, Young BW. Copper metabolism in rats given di- or trithiomolybdates. J Inorg Biochem 1982;16:109-19.
4. Mills CF, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14:163-75.
5. Gooneratne SR, Howell JM, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 1981;46:469-80.
6. McQuaid A, Mason J. A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy. J Inorg Biochem 1991;41:87-92.
7. Parke A, Bhattacherjee P, Palmer RM, Lazarus NR. Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 1988;130:173-8.
8. Raju KS, Alessandri G, Ziche M, Gullino PM. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 1982;69:1183-8.
9. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982:69:475-82.
10. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP, Brien SE. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121-42.
11. Brem SS, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 1990;26:391-6.
12. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
13. Cox C, Merajver SD, Yoo S, et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 2003;129:781-5.
14. Khan MK, Miller MW, Taylor J, et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002;4:164-70.
15. van Golen KL, Bao L, Brewer GJ, et al. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 2002;4:373-9.
16. Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003;2:617-22.
17. Cox CD, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701.
18. Kent MS, Madewell BR, Dank G, Dick RB, Merajver SD, Brewer GJ. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: A pilot study in a canine animal mode. J Trace Elem Exp Med 2004;17:9-20.
19. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10.
20. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72.
21. Brewer GJ, Ullenbruch MR, Dick RB, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-6.
22. Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-7.
23. Askari FK, Dick RB, Mao M, Brewer GJ. Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 2004;229:857-863.
24. Ma S, Hou G, Dick RD, Brewer GJ. Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 2004;4:419-26.
25. Hou G, Dick R, Abrams GD, Brewer GJ. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 2005;146:299-303.
26. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974;20:1556-63.
27. Palmer G, Chobaz V, Talabot-Ayer D, et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum 2004;50:4051-9.
28. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 2006;100:927-930.
29. Lebecque S. A new job for dendritic cells. Nat Immunol 2001;2:830-1.
30. Teixeira LK, Fonseca BP, Barboza BA, Viola JP. The role of interferon-gamma on immune and allergic responses. Mem Inst Oswaldo Cruz 2005;100 Suppl 1:137-44.
31. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003;1:701-6.
32. Liu T, Stern A, Roberts LJ, Morrow JD. The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. J Biomed Sci 1999;6:226-35.
33. Omoto A, Kawahito Y, Prudovsky I, et al. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 2005;7:R1174-82. Epub 2005 Aug 8.
34. Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002;100:73-6; discussion 76-7.